Loading
A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Konkuk University Medical Center, completed.
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA is a phase 2 interventional study registered as NCT03228277 by Konkuk University Medical Center, with 25 participants recorded, started 2017-07-17 and reaching its primary completion in 2018-07-31. Interventions recorded: Olmutinib. Conditions recorded: Non Small Cell Lung Cancer.
Linked to the drug Olmutinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Olmutinib, Non-small-cell lung cancer and the tag pipeline.
Shares Olmutinib, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/